Core Insights - HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing fusion immunotherapeutics for chronic inflammation-related diseases, including autoimmune disorders and cancer [1][18] - The company reported financial results for the three months ended December 31, 2025, highlighting a significant decrease in revenues and a net gain for the quarter [11][15] Clinical Development - The company initiated its first-in-human clinical trial for HCW9302, targeting alopecia areata, with a focus on evaluating safety and determining recommended dose levels [2][4] - HCW9302 is designed to activate and expand regulatory T cells to suppress auto-reactive immune cells, addressing a condition that affects approximately 160 million people globally [3][4] - Preliminary human data readout from the Phase 1 study is expected in the first half of 2026 [4] Business Highlights - HCW Biologics received a $3.5 million upfront licensing fee for HCW11-006, licensed to Beijing Trimmune Biotech Co., Ltd., with potential for additional milestone payments and royalties [6][7] - The company launched two proprietary fusion protein molecules as commercial-ready reagents to support cell-based immunotherapeutics, aiming to generate revenue to offset development costs [9] Financial Performance - Revenues for Q4 2025 were $27,010, a significant drop from $394,804 in Q4 2024, with total revenues for the year decreasing from $2.6 million to $54,232 [11] - Research and development expenses increased by 27% in Q4 2025 compared to Q4 2024, while total R&D expenses for the year decreased by 15% [12] - General and administrative expenses decreased by 26% in Q4 2025, but increased by 13% for the full year [13] - The company reported a net gain of $2.2 million for Q4 2025, compared to a net loss of $3.4 million in Q4 2024, and a reduced net loss for the year from $30 million to $6.5 million [15] Financial Guidance - As of December 31, 2025, the company expressed substantial doubt regarding its ability to continue as a going concern without additional funding [16] - The company regained compliance with Nasdaq listing rules but faces ongoing monitoring and potential delisting risks due to stock price fluctuations [17]

Core Points - HCW Biologics Inc. announced a 1-for-40 reverse stock split effective April 11, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2] - The reverse stock split will reduce the number of shares outstanding from approximately 44,934,120 to about 1,123,353, while the total authorized shares will remain at 250,000,000 [3] - The reverse stock split will not affect stockholders' percentage ownership, except for those who would receive fractional shares, who will instead receive one whole share [2][3] Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies aimed at extending health span by addressing inflammation linked to age-related diseases [6] - The company utilizes two drug discovery platforms: the TOBI™ platform, which has produced several molecules including HCW9218 and HCW9302, and the TRBC platform, which employs a unique protein-based backbone for immunotherapeutics [6]